EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

10.3390/polym8030084

CrossRef Listing of Deleted DOIs · 2000

Vollständiger Abstract

Worum geht es in dieser Arbeit?

<b>Background/Objectives:</b> Histological biomarkers of therapy response remain incompletely defined in preclinical breast cancer models. We evaluated whether quantitative immunofluorescence imaging and multimodal machine learning (ML) could identify image-derived tissue biomarkers associated with response in a 4T1 murine breast cancer therapy-response setting. <b>Methods:</b> We analysed 1696 immunofluorescence images across nine immunofluorescence staining panels: aPDL1, alpha-smooth muscle actin-CD31, alpha-smooth muscle actin-Ki67, CD3-CD31, CD8-Ki67, collagen-hyaluronic acid (HA), granzyme B-CD8, HMGB1, and pimonidazole/hypoxia. A Python image-analysis algorithm extracted 117 RGB-channel, intensity, morphometric, and cross-channel spatial features per image. The modelling framework included image-only deep learning (DL), tabular ML on extracted histological features, and image-plus-tabular gated fusion. Models were evaluated using stratified cross-validation, train-fold-only class balancing, bootstrap confidence intervals, permutation testing, nested feature-selection sensitivity analysis, and grouped leakage controls. <b>Results:</b> Histological staining panels classified treatment-response status across the nine-panel benchmark. Collagen-HA was the strongest staining (AUC 0.954), followed by alpha-smooth muscle actin-Ki67 (AUC 0.851) and hypoxia (AUC 0.837). DL achieved the best performance in eight of nine stainings. In 346 collagen-HA images, combined collagen and HA features achieved AUC 0.848, collagen-only features AUC 0.833, and hyaluronic-acid-only features AUC 0.805. In 104 animals with matched hypoxia and collagen-hyaluronic-acid images, extracellular-matrix features achieved AUC 0.985, hypoxia-only features achieved AUC 0.929, and adding hypoxia did not improve extracellular-matrix-only prediction. <b>Conclusions:</b> Quantitative extracellular-matrix imaging provides a strong preclinical signal for therapy-response stratification in 4T1 breast cancer. The findings are hypothesis-generating and require independent preclinical and human validation before clinical translation.

Abstract: PubMed · Datensatz

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Nicht angegeben
Quelle
CrossRef Listing of Deleted DOIs
Publikation
2000-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0849-6757
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

(2000). 10.3390/polym8030084. CrossRef Listing of Deleted DOIs. https://doi.org/10.3390/cancers18162603
RIS BibTeX CSL-JSON